SAB生物治疗公司尽管股价差距很大,最近也蒙受了损失,但还是得到“Buy”评分。 SAB Biotherapeutics receives a "Buy" rating despite a significant stock price gap and recent losses.

SAB生物治疗公司是一家发展人体抗体以治疗免疫障碍和传染病的生物制药公司,从H.C. Wainwright获得“Buy”评级,价格目标为6.00美元。 SAB Biotherapeutics, a biopharmaceutical company developing human antibodies for immune disorders and infectious diseases, received a "Buy" rating from H.C. Wainwright, with a $6.00 price target. 尽管如此,该库存于3月27日以1.18美元开放。 Despite this, the stock opened at $1.18 on March 27th. Chardan Capital将其价格目标降至20美元, Chardan Capital lowered its price target to $20.00 but maintained a "Buy" rating. 该公司上个季度报告每股净损失1.23美元。 The company reported a net loss of $1.23 per share in its latest quarter.